MCP
LAB icon

Mirador Capital Partners’s Standard BioTools LAB Stock Holding History

Mirador Capital Partners’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-47,956
Closed -$92.6K – 196
2023
Q2 		$92.6K Buy
+47,956
New +$94.7K 0.02% 184

Other funds holding LAB

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Mirador Capital Partners's LAB Position: Q3 2023 in Review

Mirador Capital Partners sold out of Standard BioTools (LAB) in Q3 2023, closing a stake of 47,956 shares — an estimated $92.6K sold.

Mirador Capital Partners first reported a position in LAB in Q2 2023 and held it in 1 quarter. The position peaked at $92.6K in Q2 2023. 72 funds tracked by Wall St. Rank hold LAB as of Q3 2023.

  • Mirador Capital Partners reported no remaining Standard BioTools position as of Q3 2023 after selling out during the quarter.
  • Mirador Capital Partners sold 47,956 Standard BioTools shares in Q3 2023, an estimated $92.6K.
  • Mirador Capital Partners first reported a position in Standard BioTools in Q2 2023 and held it in 1 quarter.
  • Mirador Capital Partners's Standard BioTools position peaked at $92.6K in Q2 2023.
  • 72 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2023.

Based on Mirador Capital Partners's 13F filing for Q3 2023, filed 5 Oct 2023.